DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
DenTriage is a comprehensive mobile and web-based platform that will provide a convenient way for patients to receive timely guidance and care for urgent...
Project Cure CEO Douglas Jackson, PhD shares the mission of Project Cure in a wide ranging discussion that illustrates the incredible supply chain expertise...
In this episode, Ryan Khanna, MD, MBA co-hosts a discussion with Robert Eastlack who runs a premier surgical spine practice in San Diego, CA...
